Immunoconjugates targeting CD46 and methods of use thereof

Inventors

Nasoff, Marc • DORR, Andrew

Assignees

Fortis Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12144888-B2

Patent

Publication Date

2024-11-19

Expiration Date


Abstract

Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.

Core Innovation

The invention relates to treating metastatic castration resistant prostate cancer (mCRPC) in a human subject by administering a pharmaceutical composition containing an immunoconjugate. The immunoconjugate comprises an antibody that specifically binds CD46 and is conjugated to monomethylauristatin E (MMAE) via a linker comprising maleimidocaproyl-valine-citrulline-para-amino benzyloxycarbonyl.

The antibody is defined by heavy chain and light chain variable region CDR sequences, including HC CDR1 comprising SEQ ID NO: 1, HC CDR2 comprising SEQ ID NO: 2, HC CDR3 comprising SEQ ID NO: 3, LC CDR1 comprising SEQ ID NO: 4, LC CDR2 comprising SEQ ID NO: 5, and LC CDR3 comprising SEQ ID NO: 6. Exemplified antibodies include CD46-binding recombinant antibodies such as YS5FL/FOR46, with specified VH/VL CDR sequences and heavy/light sequences.

The pharmaceutical composition is administered at a dose determined from adjusted body weight (AJBW) of the human subject. The dose is from about 1.2 mg immunoconjugate per kg of the adjusted body weight to about 2.7 mg immunoconjugate per kg of the adjusted body weight, and the method targets mCRPC that comprises cells expressing CD46.

Claims Coverage

The consolidated independent claim coverage is directed to treatment of mCRPC using a CD46-binding antibody immunoconjugate with MMAE, defined linker chemistry, and AJBW-based dosing. Four inventive features are present across the independent claims.

Anti-CD46 MMAE immunoconjugate with specified CDR sequences

Administering a pharmaceutical composition containing an immunoconjugate comprising an antibody that specifically binds CD46, wherein the antibody comprises a heavy chain variable region and a light chain variable region with HC CDR1 comprising SEQ ID NO: 1, HC CDR2 comprising SEQ ID NO: 2, HC CDR3 comprising SEQ ID NO: 3, LC CDR1 comprising SEQ ID NO: 4, LC CDR2 comprising SEQ ID NO: 5, and LC CDR3 comprising SEQ ID NO: 6.

MMAE conjugation via maleimidocaproyl-valine-citrulline-para-amino benzyloxycarbonyl linker

The antibody is conjugated to monomethylauristatin E (MMAE) via a linker comprising maleimidocaproyl-valine-citrulline-para-amino benzyloxycarbonyl.

Adjusted body weight-determined dosing for mCRPC treatment

Administering the pharmaceutical composition at a dose determined from adjusted body weight (AJBW) of the human subject, where the dose is from about 1.2 mg immunoconjugate per kg AJBW to about 2.7 mg immunoconjugate per kg AJBW.

Treating mCRPC with CD46-expressing cells

The metastatic castration resistant prostate cancer comprises cells expressing CD46, and the mCRPC is treated.

The claim coverage centers on an anti-CD46 antibody defined by specific HC and LC CDR sequences conjugated to MMAE via a specified linker, with dosing determined by adjusted body weight within a defined mg/kg range, for treatment of mCRPC comprising CD46-expressing cells.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Not explicitly described in patent.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.